LAG3 and non-small cell lung carcinoma: In conclusion, this study identified CD137+, CD137+PD1+ T cells (total, CD4 and CD8), and the soluble immune checkpoint LAG3 as biomarkers of response to therapy in NSCLC patients under immunotherapy treatment.